The Food and Drug Administration (FDA) has approved Eylea (aflibercept; Regeneron) for the treatment of diabetic retinopathy. The Food and Drug Administration (FDA) has approved Eylea (aflibercept; ...

TARRYTOWN, N.Y. -- Regeneron Pharmaceuticals, Inc. (REGN) today announced that EYLEA ® (aflibercept) Injection has received approval for the treatment of patients with neovascular age-related macular ...

Approval based on the pivotal PULSAR and PHOTON trials in which EYLEA® HD demonstrated clinically equivalent vision gains to EYLEA (aflibercept) Injection 2 mg that were maintained with fewer ...

Regeneron Pharmaceuticals announced positive three-year results from an extension study of EYLEA HD (aflibercept) Injection 8 mg for treating wet age-related macular degeneration (wAMD). The findings, ...

TARRYTOWN, N.Y., Nov. 7, 2013 -- /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Bayer HealthCare today announced that Bayer HealthCare has submitted an application for marketing ...

Please provide your email address to receive an email when new articles are posted on . The approval was based on results of the phase 3 PANORAMA trial, which enrolled 402 patients to investigate ...

today announced that the U.S. Food and Drug Administration has approved EYLEA Injection, known in the scientific literature as VEGF Trap-Eye, for the treatment of patients with neovascular Age-related ...

Key Points Interested in Eyepoint Pharmaceuticals, Inc.? Here are five stocks we like better. EyePoint Pharmaceuticals said ...

New presentations include final 64-week results from the Phase 3 QUASAR trial in patients with retinal vein occlusion, as well as full primary results from the Phase 3b ELARA trial in patients treated ...

TARRYTOWN, N.Y., Aug. 6, 2013 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Bayer HealthCare today announced that in the Phase 3 VIVID-DME and VISTA-DME trials of EYLEA ® ...

today announced that EYLEA® (aflibercept) Injection has been approved by the European Commission for the treatment of patients with neovascular (wet) age-related macular degeneration (wet AMD).